Publications, Abstracts, and Posters
Michael Morse, Sandip Pravin Patel, Melony A. Beatson, Philip M. Arlen. A phase II study of NPC-1C: A novel therapeutic monoclonal antibody (mab) to treat pancreatic (P) and colorectal (CR) cancers. J Clin Oncol 31, 2013 (suppl; abstr 3070).
Sandip P. Patel, Michael A. Morse, Luiz A. Diaz, Nilofer S. Azad, Sherri Haley, Phil M. Arlen. A phase I safety study of NPC-1C, a novel, therapeutic antibody to treat pancreas and colorectal cancers: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract LB-61.
Arlen M, Arlen P. Optimizing the immune system to achieve control of the metastatic malignant lesion.<http://www.ncbi.nlm.nih.gov/pubmed/23833687> J Cancer. 2013 Jun 28;4(5):427-32. doi: 10.7150/jca.6572
Sandip Pravin Patel, Michael Morse, Muhammad Shaalan Beg, Nilofer Saba Azad, Melony A. Beatson, Sharon Mavroukakis, Philip M. Arlen.
A phase Ib/IIa study of NEO-102: A therapeutic antibody to treat pancreatic and colorectal cancers. J Clin Oncol 32, 2014 (suppl 3; abstr 243).
Arlen M, Arlen P, Coppa G, Crawford J, Wang X, Saric O, Dubeykovskiy A, Molmenti E. Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer.<http://www.ncbi.nlm.nih.gov/pubmed/24936227> World J Gastrointest Oncol. 2014 Jun 15;6(6):170-6. doi: 10.4251/wjgo.v6.i6.170.
Muhammad Shaalan Beg, Michael Morse, Sandip P. Patel, Sharon Mavroukakis, Melony Beatson, Philip M. Arlen, Nilofer S. Azad. A Phase I/IIA multicenter clinical trial of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic and colorectal cancer: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; 2014. Abstract CT415.
Sandip Pravin Patel, Michael Morse, Muhammad Shaalan Beg, Nilofer Saba Azad, Melony A. Beatson, Sharon Mavroukakis, Philip M. Arlen. A phase Ib/IIa study of NEO-102: A therapeutic antibody for the treatment of advanced pancreatic and colorectal cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 3072)
Arlen M., Crawford J., Coppa G., Saric O., Bandovic J., Doubakovski A., Sullivan J., Conte C., Kadison A., Procaccino J., Arlen P., Wang X., Molmenti E. The Cause and Prevention of Anastomotic Recurrence following Colectomy: An Immunohistochemical Approach for Detecting Transforming Colonocytes. J Cancer 2014; 5(9):784-789. doi:10.7150/jca.9485.
Patel S, Bristol A, Saric O, Wang X, Dubeykovskiy A, Arlen M, Morse M. Anti-Tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. Cancer Immunol Immunother. (2013) Download PDF
Arlen M, Wang X, Luka J, Gupta R, Saric O, Arlen PM. The Use of Specific Monoclonal Antibodies to Target Immunogenic Tumor Membrane Proteins in Patients with Recurrent Pancreatic and Colon Cancer. Curr Drug Deliv. 2012 Jan 5
Michael Morse, Luis A. Diaz, Nilofer Saba Azad, Dan Laheru, Sherri Haley, Leanne Sophia Sleer, Philip M. Arlen. A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers. J Clin Oncol 30, 2012 (suppl 4; abstr 233).
J. A. Bristol, J. Luka, M. Semenuk, I. H. Sbeitan, M. Thomas, P. M. Arlen. A novel antibody that can detect a serum biomarker: Utility for detection and prognosis in colorectal and pancreatic cancer.J Clin Oncol 29: 2011 (suppl; abstr e21121).
N. S. Azad, L. A. Diaz, C. E. Devoe, D. Laheru, D. T. Le, D. Cosgrove, L. Zheng, A. De Jesus-Acosta, R. C. Donehower, P. M. Arlen, J. A. Bristol. A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers. J Clin Oncol 29: 2011 (suppl; abstr TPS141)
J Luka, P. M. Arlen, J. A. Bristol. Development of a new stool biomarker ELISA for the early detection of colorectal cancer.J Clin Oncol 29: 2011 (suppl 4; abstr 390).
M. di Bari, A. Spila, P. M. Arlen, J. A. Bristol, M. Roselli, F. Guadagni. Use off two novel antibodies that detect tumor-specific antigens for the detection of colorectal cancer.J Clin Oncol 29: 2011 (suppl; abstr e21082).
J Luka, P. M. Arlen, A. Bristol. Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC.J Biomed Biotechnol. 2011;2011:934757. Epub.
Arlen M, Arlen P, Tsang A, Wang X, Gupta R. The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.J Cancer. 2010;1:209-22.
“A Novel Antibody That Can Detect a Serum Biomarker: Utility for Detection and Prognosis in Colorectal and Pancreatic Cancer” abstract from the American Association for Cancer Research’s first special conference on Colorectal Cancer: Biology to Therapy.
“Diagnostic/prognostic utility of a new serum biomarker ELISA for colorectal and pancreatic cancers” abstract from 2010 American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Markers in Cancer.
Arlen PM, Kantor J, Luka J, Saric O, Gupta R, Arlen M and Bristol A. Preclinical development of a novel therapeutic antibody to treat pancreas and colorectal cancers Mol Cancer Ther 2009;8(12 Suppl):B124.
Arlen M, et al. The identification and development of specific monoclonal antibodies to squamous cell carcinoma. Critical Rev. Immunol. 21:205-214, (2001).
Takita H, Hollinshead AC, Adler RH, et al. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5 year survival analysis. J Surg Oncol. 46(1):9-14, (1991).
Arlen M, and Tsang, K. The nature of the monoclonal antibodies derived from immunogenic membrane antigens of human colon carcinoma origin. J. Tumor Marker Oncol. 5:313-319, (1990).
Hollinshead A, Takita H, Stewart T, and Raman S. Specific active lung cancer immunotherapy. Immune correlates of clinical responses and an update of immunotherapy trials evaluations. Cancer 62:1662-1671 (1988).
Hollinshead A, Stewart TH, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Tumor associated antigens. Cancer 60(6): 1249-62, (1987).
Hollinshead A, Elias EG, Arlen M, et al. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor–associated antigens (TAA). A phase I clinical trial. Cancer 56(3):480-9, (1985).
Hollinshead A, Arlen M, Yonemoto R, et al. Pilot studies using melanoma tumor-associated antigens (TAA) in specific active immunochemotherapy of malignant melanoma Cancer 49:1387 (1982).
Hollinshead A, Miller H, Tanner K, Lee O, and Klausia J. Soluble cell membrane antigens associated with bladder cancer. Cancer Immunol. Immunother. 5:93-103, (1978).
Char D, Hollinshead A, and Herberman R. Skin tests with soluble melanoma antigens in patients with choroidal tumors. Cancer 40:1650-1654 (1977).
Hitchcock M, Hollinshead A, Chretien P, and Rizzoli H. Soluble membrane antigens of brain tumors. Controlled testing for cell-mediated immune responses in a long surviving glioblastoma multiforme patient. Cancer 40:660-666, (1977).
Hollinshead A, Herberman R, Jaffurs W, et al. Soluble membrane antigens of human malignant melanoma cells. Cancer 34:1235-1243, (1974).
Hollinshead A, Jaffurs W, Alpert L, et al. Isolation and identification of soluble skin-reactive membrane antigens of malignant and normal human breast cells. Cancer Res. 34:2961-2968, (1974)
Patel SP, Bristol A, Saric O, Wang XP, Dubeykovskiy A, Arlen PM, Morse MA. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. Cancer Immunol Immunother. 2013 Jun;62(6):1011-9. doi: 10.1007/s00262-013-1420-z
Muhammad S. Beg1, Nilofer S. Azad2, Sandip P. Patel3, Jose Torrealba 4, Sharon Mavroukakis5, Melony A. Beatson5, Xue Ping Wang5, Philip M. Arlen5, Michael A. Morse6. A Phase 1 dose escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemotherapy and Pharmacology (in Press)